Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Highlights this week included:
Indian generics Aurobindo Pharma Limited and MedChem join Medicines Patent Pool (Spicy IP) (IP Watch) (IPBiz)
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
General
Australian Senate Committee issues recommendation on Gene Patenting Bill (Patent Docs)
EU: Paediatrics and transitional periods: a reader writes (The SPC Blog)
Indian generics Aurobindo Pharma Limited and MedChem join Medicines Patent Pool (Spicy IP) (IP Watch) (IPBiz)
Italy: Generics can be sued in the courts of the pharmacies, says the Court of Turin (Kluwer Patent Blog)
US: Appealing premarket disputes in the Device Center: Reform is needed (FDA Law Blog)
US: Lawyer, physician, and bioethicist takes over the reins at FDA’s orphan drug shop (FDA Law Blog)
US: Are prenatals marketed as unapproved drugs exempt from FDA’s September 19 guidance? No (FDA Law Blog)
US: Patent battle over modified meganucleases heats up: Cellectis v Precision Biosciences (Holman’s Biotech IP Blog) (Patent Docs)
US: Landmark NORD report on orphan drugs authored by HP&M Director shows FDA flexibility in approval (FDA Law Blog)
Products
Embeda (Morphine sulfate, Naltrexone hydrochloride) – US: Pfizer, Alpharma, King Pharma. file patent infringement suit against Watson following Para IV certification (Patent Docs)
Exelon (Rivastigmine) – UK: EWHC (Pat): Rivastigmine patent, SPC held invalid: Generics (UK) Ltd (t/a Mylan) v Novartis AG (The SPC Blog)
Nexavar (Sorafenib) – India: The absence of evidence in NATCO’s CL application for Nexavar (Spicy IP)
Targretin (Bexarotene) – US: Eisai file patent infringement complaint against Banner Pharmacaps in response to Para IV certification (Patent Docs)
Tavanic (Levofloxacin hemihydrate) – EU: TRIPS case heading for the ECJ has an SPC in the underlying dispute: Case C-414/11 Daiichi Sankyo Company Limited, Sanofi-Aventis Deutschland GmbH v DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon (The SPC Blog) (IPKat)